Applied Micro Circuits Corp. (Nasdaq:AMCC) announced that it will conduct a conference call with analysts and investors following the release of its third quarter fiscal 2011 results on Thursday, January 27, 2011. AppliedMicro will issue a news release announcing the company's third quarter fiscal 2011 results after the close of the market on January 27. The text of the press release will also be available on AppliedMicro's web site. The conference call will be webcast from the investor relations section of the company's web site beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on January 27.
Applied Micro Circuits Corporation designs, develops, markets, and supports integrated circuits for processing, transporting, and storing of information worldwide.
Power3 Medical Products, Inc. (OTC.BB:PWRM) a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced that company management believes it is making great progress in its focus on the development, sales, and marketing of its proprietary innovate diagnostic tests for breast cancer, pancreatic cancer, ovarian cancer, colon cancer, and certain neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, to name a few.
“We are very excited to be finally ridding ourselves of litigation that has plagued us for several years now,” stated Ira L. Goldknopf, President and Chief Scientific Officer of Power3 Medical Products, Inc. “We have big plans for the future beginning with our upcoming acquisition of Rozetta-Cell and are about to enter a long and substantial growth phase marked by advances in our science and intellectual property. Given the imminent nature of many of these transactions and breakthroughs, we have decided, in consultation with the financiers of Rozetta-Cell, that the best course of action for Power3 is to settle many of these lawsuits so that we can focus our attention exclusively on the acquisition of Rozetta-Cell and the development of our combined businesses after the merger.”
Rozetta-Cell Life Sciences, Inc. is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. Power3 plans to effect the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company. The acquisition of Rozetta-Cell is expected to be completed in February 2011.
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.
Orofino Gold Corp. (ORFG.PK) is a US (Nevada) company established for the purpose of creating a significant exploration and mining group to operate in Colombia.
Orofino has major criteria by which they select properties that includes:
* Significant historical production
* Favorable geology for hosting major ore bodies
* Significant property area for large target exploration
* Recent results available
* Favorable infrastructure and access to allow mine development
* Receptive local government and populace.
In addition, Orofino has acquired a database comprised of exploration and mining results from previous operators who left when the global mining sector experienced a major downturn in the three year period from 1997-2000
The second part of the Company’s strategy to become a recognized player in the Colombia mining sector was the acquisition of an interest in an operating mine. The Company has acquired a 55% interest in the La Azul/La Estrella property with the rights to acquire up to 80%.
Orofino Gold Corp. has several Gold development properties in Colombia, a current hot spot of gold production in the world markets.
Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) announced the appointment of Dr. Hank McKinnell to its Board of Directors. Dr. McKinnell is the former Chief Executive Officer and former Chairman of the Board of Directors of Pfizer Inc. He is currently Chairman of the Accordia Global Health Foundation, an organization dedicated to fighting infectious diseases in Africa, and is a member of the boards of Moody's Corporation, Angiotech Pharmaceutical, Inc., and privately-held Emmaus Medical, Inc.
Optimer Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing anti-infective products worldwide.
Electronics for Imaging, Inc. (Nasdaq:EFII) a world leader in customer-focused digital printing innovation, announced that it will hold its quarterly conference call to discuss fourth quarter and fiscal 2010 results on Thursday, January 20th, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). The conference call will be webcast and investors will be able to access the conference call and slide presentation at the Investor Relations/Events & Presentations portion of EFI's web site.
Electronics For Imaging, Inc. provides color digital print controllers, format printers and inks, and print management solutions worldwide.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.
Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).
Crown Equity Holdings Inc. (OTCPK:CRWE) has received 500,000 shares of 144 stock in Orofino Gold Corp. (PINK SHEETS: ORFG) valued at sixty five thousand dollars, and 500,000 shares of free trading shares valued at sixty five thousand dollars from a third party (QU CUI You) for 30 days advertising .